Oddo BHF Asset Management Sas Purchases Shares of 162,313 Caris Life Sciences, Inc. $CAI

Oddo BHF Asset Management Sas acquired a new stake in Caris Life Sciences, Inc. (NASDAQ:CAI) in the 4th quarter, Holdings Channel.com reports. The institutional investor acquired 162,313 shares of the company’s stock, valued at approximately $4,379,000.

Several other institutional investors have also modified their holdings of the stock. Temasek Holdings Private Ltd bought a new stake in shares of Caris Life Sciences in the 4th quarter valued at approximately $330,000. Squarepoint Ops LLC bought a new stake in Caris Life Sciences during the 4th quarter valued at $1,737,000. PEAK6 LLC raised its position in Caris Life Sciences by 6.9% during the 4th quarter. PEAK6 LLC now owns 24,800 shares of the company’s stock valued at $669,000 after purchasing an additional 1,600 shares in the last quarter. Maven Securities LTD purchased a new position in shares of Caris Life Sciences in the 4th quarter valued at $1,079,000. Finally, Knollwood Investment Advisory LLC purchased a new position in shares of Caris Life Sciences in the 4th quarter valued at $282,000.

Caris Life Sciences Price Performance

Shares of Caris Life Sciences stock opened at $17.98 on Wednesday. The company has a quick ratio of 6.52, a current ratio of 7.05 and a debt-to-equity ratio of 0.64. The firm’s 50 day moving average price is $17.74. The firm has a market capitalization of $5.08 billion and a PE ratio of -2.36. Caris Life Sciences, Inc. has a 12 month low of $14.19 and a 12 month high of $42.50.

Caris Life Sciences announced that its board has initiated a share repurchase plan on Monday, June 8th that authorizes the company to repurchase $100.00 million in shares. This repurchase authorization authorizes the company to purchase up to 2.2% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on CAI. Piper Sandler began coverage on Caris Life Sciences in a report on Friday, April 10th. They issued a “neutral” rating and a $21.00 price target on the stock. The Goldman Sachs Group assumed coverage on Caris Life Sciences in a research report on Wednesday, April 1st. They set a “buy” rating and a $27.00 price target for the company. BTIG Research lowered their price target on Caris Life Sciences from $38.00 to $32.00 and set a “buy” rating for the company in a research report on Friday, May 8th. New Street Research began coverage on Caris Life Sciences in a report on Friday, May 8th. They issued a “market perform” rating for the company. Finally, Jefferies Financial Group initiated coverage on Caris Life Sciences in a report on Monday, April 13th. They issued a “buy” rating and a $28.00 price objective for the company. Six investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Caris Life Sciences currently has a consensus rating of “Hold” and a consensus target price of $27.56.

Insider Activity

In related news, Director Jeff L. Vacirca purchased 31,050 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was acquired at an average cost of $16.15 per share, for a total transaction of $501,457.50. Following the completion of the transaction, the director directly owned 49,671 shares of the company’s stock, valued at approximately $802,186.65. This trade represents a 166.75% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 50.00% of the stock is owned by company insiders.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.